Avatar for Polaris Partners

Tech and Life Science Venture Capital

Tech and Life Science Venture Capital

Since 1996, Polaris has been guided by the fundamental beliefs that people come first and true partnerships make all the difference.

Rooted in mutual respect and a shared passion for innovation, our relationships with outstanding visionaries principally in technology and healthcare have helped to change the world for the better.

Polaris Partners hasn't added any jobs yet

Get notified when Polaris Partners posts new jobs.

See similar jobs

Latest Stories and News

FloQast raises $40M Series C led by Norwest on record of strong ARR growth, ACV expansion

  • TechCrunch
  • 4 months ago
  • FloQast, a Los Angeles, CA-based provider of close management software for accountants, raised $40m in Series C funding.
  • The round, which brought total equity raised to date to $93m, was led by Norwest Venture Partners with participation from existing investors Insight Partners and Polaris Partners.
  • The company intends to use the funds to further accelerate customer expansion and drive continued technology innovation for corporate accounting teams.
  • Led by Mike Whitmire, co-founder and CEO, FloQast provides cloud-based close management software, which integrates with ERPs and leverages existing checklists and Excel to provide a single place to manage the month-end close and gives everyone visibility.
FloQast raises $40M Series C led by Norwest on record of strong ARR growth, ACV expansion

Freenome Closes $160 Million Series B Financing to Advance Early Cancer Detection

  • Businesswire
  • 10 months ago

Freenome, a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw, today announced the close of its $160 million Series B financing, bringing its total financing to $238 million to date.

Freenome will use the proceeds to further the development of its early cancer detection blood test powered by its platform. The Company plans to conduct a pivotal validation study and submit to the U.S. Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS) under the Parallel Review Program the first application of its platform in colorectal cancer screening and expand its laboratory infrastructure and software to support its continued growth.

The Series B financing was led by RA Capital Management and Polaris Partners. They were joined by other new investors including Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., Roche Venture Fund, Kaiser Permanente Ventures, and the American Cancer Society’s BrightEdge Ventures. Freenome’s existing investors also participated in the financing including Andreessen Horowitz, GV (formerly Google Ventures), Data Collective Venture Capital, Section 32, and Verily Life Sciences (a subsidiary of Alphabet focused on life sciences and healthcare).

Freenome Closes $160 Million Series B Financing to Advance Early Cancer Detection

jonathan flint

Avatar for jonathan flint